50% of patients treated with Kanuma experience reduced liver fibrosis: 3 study insights

New Haven, Conn.-based Alexion Pharmaceuticals has released data from studies related to the Phase 3 ARISE trial of Kanuma. Kanuma, or sebelipase alfa, is a drug treatment for lysosomal acid lipase deficiency.

Here's what you need to know:

1. Two-thirds of patients treated with Kanuma for 52 weeks experienced reduced liver fibrosis.

2. Half of patients treated with Kanuma for 52 weeks experienced at least a two-stage reduction in liver fibrosis.

3. Kanuma-treated patients also experienced improvements in alanine aminotransferase, LDL cholesterol and liver fat content.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast